PARP inhibition in cancer: an update on clinical development
E Sachdev, R Tabatabai, V Roy, BJ Rimel, MM Mita - Targeted oncology, 2019 - Springer
Abstract PARP (poly (ADP-ribose) polymerase) inhibitors represent a novel class of anti-
cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting …
cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting …
PARP inhibitors: A new era of targeted therapy
Personalized medicine seeks to utilize targeted therapies with increased selectivity and
efficacy in preselected patient cohorts. One such molecularly targeted therapy is enabled by …
efficacy in preselected patient cohorts. One such molecularly targeted therapy is enabled by …
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications
Y Drew, R Plummer - Drug Resistance Updates, 2009 - Elsevier
The abundant nuclear enzyme poly (ADP-ribose) polymerase-1 (PARP-1) represents an
important novel target in cancer therapy. PARP-1 is essential to the repair of single strand …
important novel target in cancer therapy. PARP-1 is essential to the repair of single strand …
[HTML][HTML] A decade of clinical development of PARP inhibitors in perspective
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
Structural implications for selective targeting of PARPs
JD Steffen, JR Brody, RS Armen, JM Pascal - Frontiers in oncology, 2013 - frontiersin.org
Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that use NAD+ as a
substrate to synthesize polymers of ADP-ribose (PAR) as post-translational modifications of …
substrate to synthesize polymers of ADP-ribose (PAR) as post-translational modifications of …
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
X Jiang, W Li, X Li, H Bai, Z Zhang - Cancer management and …, 2019 - Taylor & Francis
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted agents for
the treatment of solid tumors. Concurrent PARP inhibition in Breast Cancer Susceptibility …
the treatment of solid tumors. Concurrent PARP inhibition in Breast Cancer Susceptibility …
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
A mounting body of evidence now indicates that PARP inhibitors have the potential to be
used as a foundation for both monotherapy and combination strategies across a wide …
used as a foundation for both monotherapy and combination strategies across a wide …
[HTML][HTML] A review of PARP inhibitors: from bench to bedside
C Underhill, M Toulmonde, H Bonnefoi - Annals of Oncology, 2011 - Elsevier
Background Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, with
novel and selective mechanisms of action, have moved from the laboratory to the clinic in …
novel and selective mechanisms of action, have moved from the laboratory to the clinic in …
相关搜索
- clinical development parp inhibition
- update on clinical development
- cancer therapy parp inhibitors
- brca mutant parp inhibitors
- cancer therapy clinical applications
- selective targeting structural implications
- parp inhibitor ovarian cancer
- cancer cell parp inhibitors
- clinical applications parp inhibitors
- targeted therapy parp inhibitors
- cancer cell clinical applications